JENNIFER LANDRETTE: Open Payments
NPI 1609193671 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,109 in 55 payments from 10 companies in 2025. Trend: 2023 $101 · 2024 $264 · 2025 $1,109
Food & beverage: $1,109
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $230 |
| E.R. Squibb & Sons, L.L.C. | 16 | $216 |
| Neurocrine BioSciences, Inc. | 5 | $158 |
| Janssen Pharmaceuticals, Inc | 3 | $130 |
| Teva Pharmaceuticals USA, Inc. | 5 | $119 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| ABBVIE INC. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Lundbeck LLC | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: ARISTADA, COBENFY, INGREZZA, INVEGA SUSTENNA, FANAPT, ABILIFY ASIMTUFII, UZEDY, VRAYLAR.
Industry payments across DC — which companies pay providers there.
